Molecular docking analysis of alkaloid compounds with beta-catenin towards the treatment of colon cancer

Rajagopal Ponnulakshmi1, Veeraraghavan Vishnupriya2, Surapaneni Krishna Mohan3, Srinivasan Abilasha4, Govindan Ramajayam5, Periyasamy Vijayalakshmi6, Manikkam Rajalakshmi6, Jayaraman Selvaraj2*

1Central Research Laboratory, Meenakshi Academy of Higher Education and Research (Deemed to be University), Chennai-600 078, India; 2Department of Biochemistry, Saveetha Dental College and Hospitals, Saveetha Institute of Medical and Technical Sciences, Saveetha University, Chennai - 600 077, India; 3Department of Biochemistry, Panimalar Medical College Hospital & Research Institute, Varadharajapuram, Poonamallee, Chennai-600 123, Chennai, Tamil Nadu, India; 4Department of Anatomy, Asan Memorial Dental College & Hospital, Asan Nagar, Chengalpattu, Tamil Nadu, India; 5Multi Disciplinary Research Unit, Madurai Medical College, Tamil Nadu, India; 6DBT-BIF Centre, PG & Research Department of Biotechnology & Bioinformatics, Holy Cross College (autonomous), Trichy, Tamil Nadu, India; Dr. Jayaraman Selvaraj - E-mail: jselvaendo@gmail.com; *Corresponding author:

Received February 15, 2019; Revised March 10, 2020, Accepted March 18, 2020; Published March 31, 2020

Declaration on official E-mail:
The corresponding author declares that official e-mail is not available for all authors from their institution

Declaration on Publication Ethics:
The authors state that they adhere with COPE guidelines on publishing ethics as described elsewhere at https://publicationethics.org/. The authors also undertake that they are not associated with any other third party (governmental or non-governmental agencies) linking with any form of unethical issues connecting to this publication. The authors also declare that they are not withholding any information that is misleading to the publisher in regard to this article.

Abstract:
It is known that beta-catenin is associated with fibromatosis, sarcoma and mesenchymal tumor. Therefore, it is of interest to design an effective inhibitor to the target protein beta-catenin. In this study, we report the molecular docking analysis of alkaloid compounds (aristolochic acid, cryptopleurine, demecolcine, fagaronine and thalicarpine) with beta-catenin for further consideration towards the design and development of potential inhibitors for the treatment of colon cancer.

Keywords: Colon cancer, β-catenin, Molecular docking, ADME
Background:
The WNT/β-catenin pathway is implicated in many forms of human disease including cancer. β-catenin, a key factor in the Wnt signaling involved in the tumorigenesis of colorectal cancer. The high expression and dysregulation of β-catenin, which is related to the Wnt signaling pathway, is involved in various human diseases, especially colon cancers [1, 2]. β-Catenin, a messenger molecule relevant to growth and survival is degraded through the ubiquitin-proteasome pathway. Recently, evidence has also indicated that the dysregulation of Wnt/β-catenin signaling has been implicated in hematological malignancies, including MM [3]. The related factors include increased expression of Wnt transcriptional cofactors and associated micro RNAs and disturbed epigenetics and posttranslational modification processes [4, 5]. WNT/β-catenin signaling is also an evolutionarily conserved pathway that plays a crucial role in cellular proliferation, differentiation, and migration in multiple organ systems [6]. WNT activation can induce two different pathways, the β-catenin-dependent canonical pathway and the β-catenin-independent non-canonical pathway. In the absence of WNT ligands, β-catenin is recruited and degraded by the destruction complex. Binding of WNT to its receptors disrupts the destruction complex, thereby inducing cytoplasmic accumulation of β-catenin and subsequent translocation to the nucleus [7]. Over 90% of colorectal cancer is carried out by somatic mutations in Wnt signalling constituent genes like adenomatous polyposis coli (APC) tumor suppressor gene and β-catenin genes, resulting in constitutive activation of Wnt signalling [8]. This in turn guides to the generation of colon cancer, which are intrinsically resistant to conventional chemotherapy. Genetic changes in the adenomatous polyposis coli (APC) gene have been recognized in familial adenomatous polyposis coli and determined in a group of sporadic colorectal cancers [9]. Hence, therapeutics that can block Wnt signaling are possible to get rid of cancer cells and treat the disease. Therefore, discovery of new genes involved or deregulated in CRCs may give vital insights for development of new sustainable therapeutic interventions. In order to design new inhibitor that deregulate the β-catenin activity ten natural alkaloid compounds were selected for the present study (Table 1).

Methods:
Protein preparation:
High-resolution structure of Beta-catenin (Figure 1) was downloaded from PDB (PDB ID: 1JDH) [10]. In the first of protein preparations removing other chains expect A chain and then water molecules which was observed crystallographic ally was removed. Finally prepared protein was uploaded to the Patch dock server for docking studies.

Ligand preparation:
In our present study, selected ten natural alkaloid compounds were retrieved from pubchem database in SDF format and it was converted as PDB file format using Online Smile Translator. Energy minimizations of ligands were performed using by ChemBio 3D Ultra 12.0, based on the reported method. Energy minimized structures of ligands were uploaded in patch dock for docking analysis.

| S. No | Compound name | Source of plant |
|-------|----------------|-----------------|
| 1     | Aristolochic acid | Aristolochia indica L. |
| 2     | Camptothecin | Camptotheca acuminata Decne |
| 3     | Colchicine | Colchicum speciesium Steven |
| 4     | Cryptoleurine | Crinum macrantherium Engl |
| 5     | Epipodophyllotoxin | Podophyllum species L. |
| 6     | Derrmocline | Derrmciumspeciosum Steven |
| 7     | Fagaronine | Fagara zanthoxyloides Lam |
| 8     | Oxyacanthine | Berberis asiatica Roxb. |
| 9     | Thalicarpine | Thalictrum dasyacarpum Fisch |

Table 2: Molecular docking results obtained through Patch dock server

| S. No | Compound name | Score | ACE |
|-------|----------------|-------|-----|
| 1     | Aristolochisacid | 3972 | -133.63 |
| 2     | Cryptoleurine | 4662 | -191.07 |
| 3     | Derrmocline | 4932 | -131.13 |
| 4     | Fagaronine | 4278 | -133.21 |
| 5     | Thalicarpine | 6476 | -172.51 |

Table 3: Calculated molecular Descriptors using Mol inspiration

| Compound name | Mowat | Dipole | N atom | MW | N oH | N oH-NH | N Violation | volume |
|---------------|-------|--------|--------|-----|------|---------|------------|--------|
| Aristolochisacid | 5.35 | 1.01 | 25 | 341.3 | 8 | 1 | 0 | 0 | 3 | 371.8 |
| Cryptoleurine | 4.55 | 3.09 | 28 | 377.4 | 4 | 0 | 0 | 3 | 357.4 |
| Derrmocline | 1.74 | 66.0 | 27 | 371.6 | 6 | 1 | 0 | 0 | 3 | 357.4 |
| Fagaronine | 0.0 | 51.8 | 26 | 350.4 | 5 | 1 | 0 | 3 | 316.3 |

- Logarithm of partition coefficient between n-octanol and water (miLogP).
- Topological polar surface area (TPSA).
- Number of hydrogen bond acceptors (n-OH).
- Number of hydrogen bond donors (n-OH-NH).
- Number of rotatable bonds (n-robt).
- Percentage of absorption (%ABS).
- Molecular weight (MW)

Molecular docking:
The Patchdock server was used to find out the interaction between β-catenine and selected natural alkaloid compounds. PatchDock identified the top first candidate solutions based on shape complementarily of soft molecular surfaces. The clustering RMSD was set to 4.0 Å as proposed by the software developer for bigger molecules and the complex type was set to default. The PatchDock algorithm splits the Connolly dot surface illustration of the molecules into concave, convex and flat patches. Then, complementary patches are coordinated in order to create the candidate transformations of docked complex (the candidate transformations are the docked complexes of specified receptor and

ISSN 0973-2063 (online) 0973-8894 (print) 284 ©Biomedical Informatics (2020)
ligand molecule based on the patchdock theory). The result was retrieved from the e-mail address given and downloaded [11,12].

Table 4: Calculated ADME Properties

| Compound name   | Molecular Mass a | Hydrogen bond donor b | Hydrogen bond acceptor c | LogP d | Molar Refractivity e |
|-----------------|------------------|-----------------------|--------------------------|--------|----------------------|
| Aristolochicacid| 341              | 1                     | 7                        | 3.33699| 87.742668            |
| Cryptopleurine   | 377              | 0                     | 4                        | 4.691699| 111.929962           |
| Demecoline       | 371              | 1                     | 6                        | 2.66494| 103.625674           |
| Figaroline       | 350              | 1                     | 4                        | 3.341899| 99.786171            |
| Thalicarpine     | 696              | 0                     | 10                       | 5.341899| 68.041779            |

*Molecular mass less than 500 Dalton; *High lipophilicity (expressed as LogP) less than 5; *Less than 5 hydrogen bond donors; *Less than 10 hydrogen bond acceptors; *Molar refractivity should be between 40-130

Figure 1: Structure of the beta-catenin

**Molecular descriptors calculation:**
Smiles notation of compounds was used to calculate the molecular descriptors of selected compounds using Molinspiration (www.molinspiration.com). They molecular descriptors like log P, molecular weight, polar surface area, number of atoms, number of rotatable bond, number of O or N, number of OH or NH, ion channel modulator, drug-like ness and number of violations to Lipinski’s rule were calculated in the present study [13].

**Analysis of ADME of selected compounds:**
The ADME calculation of selected natural compounds was performed by Lipinski filter (http://www.scbio-itd.res.in/software/drugdesign/lipinski.jsp), according to which an orally active drug must obey at least of four of the five laid down criterion for drug likeness namely: molecular mass, cLogP, hydrogen donor and acceptor and molar refractive index [14].

**Results and Discussion:**
We took 10 alkaloid groups of natural compounds for the study. Based on the analysis of docking studies best five were shown in Table 2. The atomic contact energy (ACE) value of selected 5-alkaloid compounds range from -191.07 to -131.13 Kcal/. Thus from the calculated ACE values it can be inferred that these compounds showed the favorable binding energy with beta-catenin protein.

Ligplot analysis shows the hydrogen bonding and the length of their interaction with the key residues of the beta-catenin in the active site pocket. Among the residues which play a vital role in the mechanisms of action we found that the SER 20, ASN 34, LYS 22, LYS 270, SER 351, ARG 469, LYS 345 are the main interacting amino acids residues (Figure 2). With regard to physicochemical properties, all the five alkaloid compounds showed nil violation and complied well with the Lipinski’s rule of five as shown in Table 3. In the same way, Table 4 shows the ADME profile of the five selected alkaloids; all the ligands are predicted to have high gastrointestinal (GI) absorption effect. Thus the results of PatchDock and ADME analysis clearly showed that selected five alkaloids group of natural compounds have the capacity to inhibit the beta-catenin protein.
between β-catenin and Cryptopleurine; (c) Interaction between β-catenin and Demecolcine; (d) Interaction between β-catenin and Fagaronine; (e) Interaction between β-catenin and Thalicarpine.

**Conclusion:**
We report the binding properties of phytocompounds like Aristolochic acid, Cryptopleurine, Demecolcine, Fagaronine, Thalicarpine with beta-catenin in the context of colorectal cancer for further consideration and evaluation towards potential treatment.

**Reference:**
[1] Clevers H et al. Cell. 2012 149:1192. [PMID: 22682243].
[2] Kahn M. Nat Rev Drug Discov 2014 13:513. [PMID: 24981364].
[3] Valencia A et al. Leukemia 2009 23:1658. [PMID: 19387464].
[4] Spaan I et al. J Hematol Oncol. 2018 11:67. [PMID: 29776381].
[5] Dunach M et al. Crit Rev Biochem Mol Biol. 2017 52: 327. [PMID: 28276699].
[6] Vilchez V et al. World J Gastroenterol 2016 22: 823. [PMID: 26811628].
[7] Bahrami A et al. J Cell Biochem 2017 118: 1979-1983. [PMID: 28109136].
[8] Novellasdemunt L et al. Am J Physiol Cell Physiol. 2015 15: 9: C511-21. [PMID: 26289750].
[9] Morin P J Bioessays 1999 21:1021-1030. [PMID: 10580987].
[10] Bernstein FC, et al. Arch Biochem Biophys 1978 185: 584. [PMID: 626512]
[11] Schneidman-Duhovny D et al. Proteins. 2003 52:107. [PMID: 12784375]
[12] Schneidman-Duhovny D et al. Nucleic Acids Res. 2005 33:W363. [PMID: 15980490]
[13] Mishra H et al. Bioinformation. 2009 3: 384. [PMID: 19707563].
[14] Lipinski CA, Drug Discov Today Technol. 2004 1: 337. [PMID: 24981612].

Edited by P Kangeune

Citation: Ponnulakshmi et al. Bioinformation 16(3): 283-287 (2020)

**License statement:** This is an Open Access article which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. This is distributed under the terms of the Creative Commons Attribution License.

**Articles published in BIOINFORMATION** are open for relevant post-publication comments and criticisms, which will be published immediately linking to the original article for FREE of cost without open access charges. Comments should be concise, coherent and critical in less than 1000 words.
